Elizabeth Yeu Lin Sells 379 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Yeu Lin sold 379 shares of the stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total transaction of $26,041.09. Following the transaction, the insider directly owned 23,698 shares of the company’s stock, valued at approximately $1,628,289.58. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Thursday, March 19th, Elizabeth Yeu Lin sold 390 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $67.00, for a total transaction of $26,130.00.
• On Tuesday, March 17th, Elizabeth Yeu Lin sold 375 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $69.42, for a total transaction of $26,032.50.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $64.51 on Friday. The firm’s 50 day moving average price is $69.12 and its 200-day moving average price is $70.22. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85. Tarsus Pharmaceuticals, Inc. has a one year low of $38.51 and a one year high of $85.25. The firm has a market cap of $2.75 billion, a P/E ratio of -39.82 and a beta of 0.55.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The company had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $144.56 million. As a group, equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Rockefeller Capital Management L.P. grew its stake in Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after purchasing an additional 172 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $368,000. Invesco Ltd. boosted its stake in shares of Tarsus Pharmaceuticals by 8.0% in the 4th quarter. Invesco Ltd. now owns 1,012,357 shares of the company’s stock valued at $82,892,000 after buying an additional 75,351 shares during the period. Mackenzie Financial Corp purchased a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $202,000. Finally, XTX Topco Ltd grew its position in shares of Tarsus Pharmaceuticals by 270.3% during the fourth quarter. XTX Topco Ltd now owns 18,410 shares of the company’s stock worth $1,507,000 after buying an additional 13,438 shares in the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TARS shares. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Barclays initiated coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $100.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $91.83.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.